Search results
Results From The WOW.Com Content Network
Nirsevimab. Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). [10][11] It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor [6] that is designed to bind to the fusion protein on the surface of the RSV virus. [12][13]
In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. [2] In 2023, the company’s seat in Forbes Global 2000 was 89.
Alemtuzumab. Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein.
Sanofi added in its statement that its decision to withdraw the NDA "is not related to safety issues or deficiencies in the NDA." link The article Sanofi Delays US Application for Diabetes Drug ...
Vaccines, biopharmaceuticals. Owner. Sanofi (since 2017) Website. Official website. Protein Sciences Corporation is a biotech company based in Meriden, Connecticut. The company develops and produces vaccines and biopharmaceuticals for use against influenza and other diseases. In 2017, the company was acquired by Sanofi for $750 million.
On March 9, 2010, Sanofi-Aventis announced [6] it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint ...
For premium support please call: 800-290-4726 more ways to reach us
2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their coronavirus vaccine. They hope to have the first results of the trial by December and if it is ...